Ipamorelin 5MG

Ipamorelin peptide Canada from Maple Research Labs delivers 5mg of high-purity growth hormone secretagogue for qualified research applications.

Ipamorelin peptide Canada: a selective growth hormone secretagogue pentapeptide developed for research into pulsatile GH release mechanisms. Available from Maple Research Labs with 99.68% HPLC-UV verified purity and batch-specific COA on every order.

Product Specifications

• CAS Number: 170851-70-4
• Molecular Formula: C38H49N9O5
• Molecular Weight: 711.85 g/mol
• Purity: 99.68% (HPLC-UV verified, this batch)
• Form: Lyophilized powder
• Quantity: 5mg per vial

Ipamorelin Peptide Canada Research Summary

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that acts on the ghrelin/GHS receptor (GHSR). First described by Novo Nordisk researchers, ipamorelin is notable for its selectivity in stimulating growth hormone release without significantly affecting other pituitary hormones such as ACTH, prolactin, FSH, LH, or TSH in preclinical models. This selectivity profile has made the ipamorelin peptide Canada product a widely used research tool in neuroendocrine studies.

Unlike earlier generation growth hormone secretagogues such as GHRP-6 and GHRP-2, published research indicates that ipamorelin does not significantly stimulate appetite or elevate cortisol and aldosterone levels in animal models. This selectivity has been attributed to its specific binding characteristics at the GHSR-1a receptor.

Mechanism of Action Research

Ipamorelin acts as an agonist at the growth hormone secretagogue receptor (GHSR-1a), the same receptor targeted by the endogenous peptide ghrelin. Binding at this receptor triggers intracellular calcium signaling cascades in somatotroph cells of the anterior pituitary, leading to growth hormone release in a pulsatile pattern that mimics physiological secretion in animal models.

Published research has compared ipamorelin to other GHSR agonists including GHRP-6, GHRP-2, and hexarelin. Studies have noted that ipamorelin demonstrates dose-dependent GH release with a relatively narrow effective dose range and does not produce the desensitization observed with some other secretagogues in extended administration protocols in rodent models.

Research has also investigated ipamorelin in combination with GHRH analogs such as CJC-1295, exploring potential synergistic effects on GH secretion patterns in preclinical settings. These combination studies have examined whether simultaneous stimulation of both GHRH and GHSR pathways produces amplified or qualitatively different GH release patterns compared to either compound alone.

Preclinical Study Summary

Ipamorelin has been investigated in multiple preclinical contexts including neuroendocrine research, bone density studies in ovariectomized rat models, and gastrointestinal motility research. Published studies span several research groups and have consistently reported its selectivity profile as a distinguishing characteristic within the GH secretagogue class.

All findings referenced are from preclinical research. No claims regarding human therapeutic applications are made or implied.

References

• Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 (PubMed)

Ipamorelin Peptide Canada Quality Assurance

Verified products of ipamorelin peptide Canada from Maple Research Labs undergoes independent third-party HPLC analysis confirming purity exceeding 98%+. Each order includes a batch-specific COA with retention time data, purity percentage, and measured fill accuracy against label claim. Our quality assurance process ensures consistent peptide integrity and purity across all shipments to Canadian research institutions.

Storage and Handling

Store at -20C lyophilized. Reconstituted peptide should be stored at 2-8C and used within 28 days. Avoid freeze-thaw cycles and direct light exposure.

Shipping

Ships same-day from our Canadian facility. Temperature-controlled packaging included.

Certificate of Analysis (COA)

For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.

Related Research Articles

• Ipamorelin vs CJC-1295: GHRP vs GHRH Research
• Ipamorelin vs Tesamorelin: Understanding the Differences
• Certificates of Analysis (COA) Documentation
• Browse All Research Peptides

Frequently Asked Questions

What is the CAS number for Ipamorelin?

The CAS registry number for Ipamorelin is 170851-70-4. It is a synthetic pentapeptide growth hormone secretagogue.

What purity does Maple Research Labs Ipamorelin achieve?

Current batch 5866 tested at 99.68% purity by independent HPLC at an independent third-party laboratory.

How should Ipamorelin be stored?

Lyophilized: -20C for 24+ months. Reconstituted in bacteriostatic water: 2-8C for up to 28 days. Ipamorelin is a stable pentapeptide under standard conditions.

Related Research Peptides from Maple Research

Researchers may also be interested in CJC-1295/Ipamorelin Blend, CJC-1295 (No DAC), and Tesamorelin 5MG. All products are shipped same-day from Canada with third-party purity verification.